Catalyst Biosciences Inc (CBIO)
0.195
0.00 (0.00%)
USD |
NASDAQ |
Mar 28, 14:13
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.141M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 115.5% |
| Valuation | |
| PE Ratio | 0.5131 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.9204 |
| Price to Book Value | 0.2090 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.24 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.99% |
News
Headline
Wire
Time (ET)
PR Newswire
03/23 14:28
PR Newswire
03/22 16:32
PR Newswire
03/16 11:45
PR Newswire
03/15 15:35
Globe Newswire
03/12 12:15
PR Newswire
03/09 21:21
PR Newswire
03/07 02:41
PR Newswire
02/28 21:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/09/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 08/15/2022 | -- | Results | Q2 2022 | -- | -- | -- | |
| 05/09/2022 | -- | Results | Q1 2022 | -- | -- | -- | |
| 11/12/2021 | -- | Results | Q3 2021 | -0.80 | -0.67 | -19.40% | |
| 08/05/2021 | -- | Results | Q2 2021 | -0.64 | -0.64 | 0.00% | |
| 05/06/2021 | -- | Results | Q1 2021 | -- | -- | -- | |
| 03/04/2021 | -- | Results | Q4 2020 | -0.88 | -0.81 | -8.64% | |
| 11/05/2020 | -- | Results | Q3 2020 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants. |
| URL | https://www.catalystbiosciences.com |
| Investor Relations URL | http://ir.catalystbiosciences.com/phoenix.zhtml?c=254141&p=irol-irhome |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 09, 2023 (est.) |
| Last Earnings Release | Aug. 15, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jan. 13, 2023 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | 0.24 |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | Jan. 13, 2023 |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 27, 2023.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 49.13M |
| Net Income (TTM) | 11.88M |
| Total Assets (Quarterly) | 31.02M |
| Total Liabilities (Quarterly) | 1.644M |
| Shareholders Equity (Quarterly) | 29.38M |
| Cash from Operations (TTM) | -49.30M |
| Cash from Investing (TTM) | 58.24M |
| Cash from Financing (TTM) | -45.01M |
Ratings
Profile
Edit
| Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants. |
| URL | https://www.catalystbiosciences.com |
| Investor Relations URL | http://ir.catalystbiosciences.com/phoenix.zhtml?c=254141&p=irol-irhome |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 09, 2023 (est.) |
| Last Earnings Release | Aug. 15, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jan. 13, 2023 |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CBIO Tweets |